Literature DB >> 25765112

MicroRNA and pediatric tumors: Future perspectives.

Rosario Gulino1, Stefano Forte2, Rosalba Parenti3, Lorenzo Memeo2, Massimo Gulisano3.   

Abstract

A better understanding of pediatric tumor biology is needed to allow the development of less toxic and more efficient therapies, as well as to provide novel reliable biomarkers for diagnosis and risk stratification. The emerging role of microRNAs in controlling key pathways implicated in tumorigenesis makes their use in diagnostics a powerful novel tool for the early detection, risk assessment and prognosis, as well as for the development of innovative anticancer therapies. This perspective would be more urgent for the clinical management of pediatric cancer. In this review, we focus on the involvement of microRNAs in the biology of the main childhood tumors, describe their clinical significance and discuss their potential use as novel therapeutic tools and targets.
Copyright © 2015 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Circulating biomarker; MicroRNA; Pediatric cancer

Mesh:

Substances:

Year:  2015        PMID: 25765112     DOI: 10.1016/j.acthis.2015.02.007

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  16 in total

Review 1.  Role of autophagy in drug resistance and regulation of osteosarcoma (Review).

Authors:  Yanchuan Pu; Jin Wang; Shizhong Wang
Journal:  Mol Clin Oncol       Date:  2022-02-01

2.  Integrative computational in-depth analysis of dysregulated miRNA-mRNA interactions in drug-resistant pediatric acute lymphoblastic leukemia cells: an attempt to obtain new potential gene-miRNA pathways involved in response to treatment.

Authors:  Hamzeh Mesrian Tanha; Marjan Mojtabavi Naeini; Soheila Rahgozar; Alireza Moafi; Mohammad Amin Honardoost
Journal:  Tumour Biol       Date:  2015-12-23

Review 3.  miR miR on the wall, who's the most malignant medulloblastoma miR of them all?

Authors:  Xin Wang; Borja L Holgado; Vijay Ramaswamy; Stephen Mack; Kory Zayne; Marc Remke; Xiaochong Wu; Livia Garzia; Craig Daniels; Anna M Kenney; Michael D Taylor
Journal:  Neuro Oncol       Date:  2018-02-19       Impact factor: 12.300

4.  MicroRNA childhood cancer catalog (M3Cs): a resource for translational bioinformatics toward health informatics in pediatric cancer.

Authors:  Wafaa M Rashed; Fatima Adel; Mohamed A Rezk; Lina Basiouny; Ahmed A Rezk; Ahmed H Abdel-Razek
Journal:  Database (Oxford)       Date:  2022-03-18       Impact factor: 4.462

5.  Expression of miR‑26a exhibits a negative correlation with HMGA1 and regulates cancer progression by targeting HMGA1 in lung adenocarcinoma cells.

Authors:  Noboru Sekimoto; Ayako Suzuki; Yutaka Suzuki; Sumio Sugano
Journal:  Mol Med Rep       Date:  2016-12-15       Impact factor: 2.952

6.  Long non‑coding RNA NR2F1‑AS1 facilitates the osteosarcoma cell malignant phenotype via the miR‑485‑5p/miR‑218‑5p/BIRC5 axis.

Authors:  Guanghui Jia; Yalei Wang; Yali Yu; Zijun Li; Xiangyu Wang
Journal:  Oncol Rep       Date:  2020-07-20       Impact factor: 3.906

7.  MicroRNA-675 directly targets MAPK1 to suppress the oncogenicity of papillary thyroid cancer and is sponged by long non-coding RNA RMRP.

Authors:  Junyi Wang; Tiantian Xiao; Ming Zhao
Journal:  Onco Targets Ther       Date:  2019-09-06       Impact factor: 4.147

Review 8.  Exosomal MiRNAs in Pediatric Cancers.

Authors:  Angela Galardi; Marta Colletti; Virginia Di Paolo; Patrizia Vitullo; Loretta Antonetti; Ida Russo; Angela Di Giannatale
Journal:  Int J Mol Sci       Date:  2019-09-17       Impact factor: 5.923

Review 9.  Comprehensive analysis on diagnostic value of circulating miRNAs for patients with ovarian cancer.

Authors:  Huiqing Wang; Tingting Wang; Wenpei Shi; Yuan Liu; Lizhang Chen; Zhanzhan Li
Journal:  Oncotarget       Date:  2017-05-24

10.  miRNA-15a regulates the proliferation and apoptosis of papillary thyroid carcinoma via regulating AKT pathway.

Authors:  Jin Jin; Jie Zhang; Yigui Xue; Li Luo; Siyao Wang; Haoming Tian
Journal:  Onco Targets Ther       Date:  2019-08-06       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.